Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced completion of enrollment in its pivotal phase 3 LUCIDITY clinical trial of avexitide for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE